Expert Panel Clears Covaxin After Promising Phase 3 Trial Data

New Delhi: Bharat Biotech’s COVID-19 vaccine Covaxin can be granted Emergency Use Approval, Drug regulator’s Subject Expert Committee (SEC) recommended on Wednesday.

Covaxin can be taken off clinical trial mode, a subject expert committee that has been monitoring the development recommended to DCGI, which will take a final call on the matter. If Covaxin is not administered under the clinical trial mode, people will not be asked to sign the consent form to take the vaccine, NDTV reported.

The recommendation of the SEC came after going through the Indian vaccine’s phase 3 trial data.

Get real time updates directly on you device, subscribe now.

Comments are closed.